ClinicalTrials.gg
Active, not recruitingNCT03260023Updated Feb 5, 2026Results posted

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

A Phase 1/2 interventional study of TG4001 and Avelumab in HPV-Related Carcinoma, HPV-Related Cervical Carcinoma and HPV-Related Anal Squamous Cell Carcinoma, sponsored by Transgene. Active, not recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Transgene · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study will consist of two parts :

In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation.

In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies.

In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in participants with HPV-16 positive advanced malignancies.

In both phases, evaluation of tumor response will be done locally according to RECIST 1.1.

All participants will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.

02

Conditions studied

  • HPV-Related Carcinoma
  • HPV-Related Cervical Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma

Browse trials for

Keywords

  • Avelumab
  • Cancer
  • Anti PD-L1
  • Therapeutic Vaccine
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 143 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Transgene is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male participants, aged at least 18 years (no upper limit of age)
  • PS 0 or 1
  • of at least 3 months
  • Participants with or cytologically documented or /recurrent HPV-16 + cancer: cervical, vulvar, vaginal, penile and anal.
  • Disease MUST not be amenable to curative surgery resection or curative radiotherapy with documented disease progression
  • Prior therapy:

    • No more than one prior systemic treatment for recurrent /metastatic disease
    • Prior treatment for recurrent or metastatic disease is not required for:

      • Participants with recurrence/progression within 6 months after completion of prior multimodal therapy for localized or locally advanced disease
      • Participants who are unsuitable for platinum-based therapy
      • Participants who refuse chemotherapy or other standard therapies for the treatment of metastatic or recurrent disease
  • Limited hepatic disease for participants with liver metastases at baseline
  • Availability of tumor tissue from
  • At least one by CT scan according to 1.1.
  • Adequate hematological, hepatic and renal function
  • Negative blood pregnancy test at screening for women of
  • Highly effective for both male and female participants if the risk of conception exists during the study period and for 3 months after the last study treatment administration

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to cancer immunotherapy including cancer vaccines, any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints)
  • Participants under chronic treatment with systemic or other drugs for a period of at least 4 weeks and whose treatment was not stopped 2 weeks prior to the first study treatment, with the exception of participants with adrenal insufficiency who may continue corticosteroids at physiological replacement dose, equivalent to ≤ 10 mg prednisone daily. Steroids with no or minimal systemic effect (topical, inhalation) are allowed
  • Participants with except those with brain metastases treated locally and clinically stable during 4 weeks prior to start of study treatment, and those without ongoing neurological symptoms that are related to the brain localization of the disease
  • Other active requiring concurrent systemic intervention
  • Participants with previous malignancies other than the target malignancy to be investigated in this trial (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
  • Participant with any organ transplantation, including stem cell transplantation
  • Known severe reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC), any history of anaphylaxis, or uncontrolled asthma
  • Any known allergy or reaction to eggs, gentamycin or attributed to compounds of similar chemical or biological composition to therapeutic vaccines/immunotherapeutic products
  • Any known allergy or reaction to any component of /PD-1 or its
  • Participants with known history or any evidence of active interstitial lung disease / pneumonitis
  • Participants with active, known, or suspected auto-immune disease or immunodeficiency, except type I diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders (such as vitiligo, psoriasis) not requiring systemic treatment
  • (that is, active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction (\< 6 months prior to enrollment), unstable angina pectoris, congestive heart failure ( Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication/active intervention, history of myocarditis
  • History of uncontrolled intercurrent illness including but not limited to:

    • Hypertension uncontrolled by standard therapies (not stabilized to 150/90 mmHg or lower)
    • Uncontrolled diabetes (e.g., ≥ 8%)
    • Uncontrolled infection
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    TG4001/Avelumab

    Biological: TG4001 · Drug: Avelumab

  • Experimental
    Avelumab

    Applicable for Phase II part 2.

    Drug: Avelumab

Interventions

  • BiologicalTG4001

    PhIb: Dose escalation PhII: Established RP2D for TG4001

  • Anti PD-L1

06

What researchers measure

Primary outcomes

  1. Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies

    Dose limiting toxicities (DLTs) includes the following: * Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded. * Liver function test abnormality: * AST or ALT \> 5 x ULN * Total bilirubin \> 3 x ULN * Concurrent AST or ALT \> 3 x ULN and total bilirubin \> 2 x ULN * Drug related AE requiring treatment interruption for more than 2 weeks

    Time frame: From Day 1 to Day 28

  2. Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1

    Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.

    Time frame: From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.

  3. Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1

    PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

    Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.

  4. Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification

    PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

    Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.

Secondary outcomes

  1. Overall Response Rate (ORR) by Using RECIST 1.1 : Phase Ib, Phase II Part 2 Cohort A

    Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.

    Time frame: From treatment start (phase Ib) / randomization (phase II part 2) : Every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.

  2. Progression Free Survival (PFS) (Phase Ib, Phase II Part 1)

    PFS is defined as the time from the date of first study treatment administration (Phase Ib, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

    Time frame: From treatment start (phase Ib, phase II part 1): Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.

  3. Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A

    Time from the date of first study treatment administration Phase Ib, Phase II part 1 or time from the date of randomization Phase II part 2 Cohort A to the date of death due to any cause. If a patient is not known to have died survival will be censored at the date of last contact.

    Time frame: From treatment start : Phase Ib, Phase II part 1 / from randomization: Phase II part 2 Cohort A through study completion, for an average of 4.5 years.

  4. Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A

    Duration of overall response in weeks (DoR) applies only to patients whose best overall response is CR or PR. The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as first documented disease progression or death due to underlying cancer.

    Time frame: From treatment start Phase Ib, Phase II part 1 / from randomization Phase II part 2 Cohort A : every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 2.5 years.

  5. Proportion of Progressive Disease Phase II Part 2 Cohort B

    Number of participants with liver metastases at baseline who has a documented disease progression as per RECIST1.1.

    Time frame: From randomization: every 6 weeks up to 24 weeks.

07

Results

Posted Dec 2, 2025

Participant flow

From 01 September 2017 through 27 March 2024, a total of 361 participants were screened. Phase Ib: 01 September 2017 until 11 April 2018 Phase II part 1: 04 October 2018 until 10 August 2020 Phase II part 2: 03 Jun 2021 until 27 March 2024

Participant flow — Overall Study
MilestonePhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab
Started3634464455
Completed3525353343
Not completed019111112
Withdrew: Adverse event0044412
Withdrew: Clinical progression0131000
Withdrew: Physician decision0001100
Withdrew: Withdrawal by subject0000300
Withdrew: Under trial intervention0025300

Outcome measures

PrimaryPhase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies

Dose limiting toxicities (DLTs) includes the following: * Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded. * Liver function test abnormality: * AST or ALT \> 5 x ULN * Total bilirubin \> 3 x ULN * Concurrent AST or ALT \> 3 x ULN and total bilirubin \> 2 x ULN * Drug related AE requiring treatment interruption for more than 2 weeks

Time frame:
From Day 1 to Day 28
Reported as:
Number · DLT
Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies
DLTPhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + Avelumab
Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies00
PrimaryPhase II Part 1: Overall Response Rate (ORR) by RECIST 1.1

Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.

Time frame:
From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
Reported as:
Number · percentage of participants
Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1
percentage of participantsPhase II Part 1 - TG4001 5x10e7 Pfu + Avelumab
Overall Response Rate16.67 (5.64 to 34.72)
Disease Control Rate (DCR)46.67 (28.34 to 65.67)
Complete Response (CR)3.33 (0.08 to 17.22)
Partial Response (PR)13.33 (3.76 to 30.72)
Stable Disease (SD)30.0 (14.73 to 49.40)
Progressive disease (PD)53.33 (34.33 to 71.66)
Statistical analysis
  • Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab ·
PrimaryPhase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1

PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

Time frame:
From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Reported as:
Median · Months
Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1
MonthsPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab
Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.13.0 (2.0 to 4.4)2.8 (1.7 to 4.2)
Statistical analysis
  • Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab vs Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab · Log Rank · p = 0.2810 · Hazard ratio (hr): 0.87 · 90% CI 0.59 to 1.29Unstratified with one-sided p-value
PrimaryProgression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification

PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

Time frame:
From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Reported as:
Median · Months
Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification
MonthsPhase II Part 2 - Cohort A - Cervix Cancer - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Cervix Cancer - AvelumabPhase II Part 2 - Cohort A - Anal Cancer - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Anal Cancer - AvelumabPhase II Part 2 - Cohort A - Genital Cancer - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Genital Cancer - Avelumab
Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification4.3 (1.7 to 12.7)2.1 (1.4 to 2.8)3.0 (1.5 to 5.6)3.0 (1.4 to NA)1.6 (1.4 to 5.6)7.2 (2.8 to NA)
SecondaryOverall Response Rate (ORR) by Using RECIST 1.1 : Phase Ib, Phase II Part 2 Cohort A

Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.

Time frame:
From treatment start (phase Ib) / randomization (phase II part 2) : Every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Using RECIST 1.1 : Phase Ib, Phase II Part 2 Cohort A
percentage of participantsPhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab
Overall Response Rate (ORR)0.050.015.213.6
Disease Control Rate (DCR)33.383.365.268.2
Complete Response (CR)0.00.08.72.3
Partial Response (PR)0.050.06.511.4
Stable Disease (SD)33.333.350.054.5
Progressive Disease (PD)66.716.734.831.8
Statistical analysis
  • Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab vs Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab · Cochran-Mantel-Haenszel · p = 0.832 (At level 0.05 without adjustments for multiplicity testing, pvalue is calculated using Cochran-Mantel-Haenszel Chi-Square test.)
SecondaryProgression Free Survival (PFS) (Phase Ib, Phase II Part 1)

PFS is defined as the time from the date of first study treatment administration (Phase Ib, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.

Time frame:
From treatment start (phase Ib, phase II part 1): Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Reported as:
Median · Months
Progression Free Survival (PFS) (Phase Ib, Phase II Part 1)
MonthsPhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + Avelumab
Progression Free Survival (PFS) (Phase Ib, Phase II Part 1)1.6 (1.4 to NA)12.0 (1.2 to NA)1.5 (1.4 to 5.5)
SecondaryOverall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A

Time from the date of first study treatment administration Phase Ib, Phase II part 1 or time from the date of randomization Phase II part 2 Cohort A to the date of death due to any cause. If a patient is not known to have died survival will be censored at the date of last contact.

Time frame:
From treatment start : Phase Ib, Phase II part 1 / from randomization: Phase II part 2 Cohort A through study completion, for an average of 4.5 years.
Reported as:
Median · Months
Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A
MonthsPhase I - TG4001 5x10e6 PfuPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab
Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A5.6 (5.6 to NA)26.2 (8.7 to NA)10.3 (6.2 to 13.3)16.6 (10.5 to 21.7)16.5 (10.0 to 19.6)
SecondaryDuration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A

Duration of overall response in weeks (DoR) applies only to patients whose best overall response is CR or PR. The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as first documented disease progression or death due to underlying cancer.

Time frame:
From treatment start Phase Ib, Phase II part 1 / from randomization Phase II part 2 Cohort A : every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 2.5 years.
Reported as:
Median · Weeks
Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A
WeeksPhase I - TG4001 5x10e6 Pfu AvelumabPhase I - TG4001 5x10e7 Pfu AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab
Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A—53.7 (40.7 to 239.7)25.1 (22.4 to 228.1)90.3 (12.1 to 138.4)55.9 (18.3 to 121.0)
SecondaryProportion of Progressive Disease Phase II Part 2 Cohort B

Number of participants with liver metastases at baseline who has a documented disease progression as per RECIST1.1.

Time frame:
From randomization: every 6 weeks up to 24 weeks.
Reported as:
Count of participants · Participants
Proportion of Progressive Disease Phase II Part 2 Cohort B
ParticipantsPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab
Non progressive disease20
Progressive disease <= 6 weeks21
Progressive disease <= 12 weeks33
Progressive disease <= 24 weeks33

Adverse events

Collected over All-cause mortality was assessed for up to 4.5 years. All non serious AEs not treatment related were reported from start of study treatment up to 30 days after last administration of study treatments through study completion for an average of 7 months. All treatment related non serious AEs and all SAEs were reported from start of study treatment up to 90 days after last administration of study treamtents through study completion for an average of 8.5 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase I - TG4001 5x10e6 Pfu + Avelumab1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase I - TG4001 5x10e7 Pfu + Avelumab0/6 (0%)4/6 (66.7%)6/6 (100%)
Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab12/34 (35.3%)18/34 (52.9%)34/34 (100%)
Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab7/46 (15.2%)16/46 (34.8%)46/46 (100%)
Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab5/44 (11.4%)18/44 (40.9%)43/44 (97.7%)
Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab1/5 (20%)2/5 (40%)5/5 (100%)
Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventPhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab
PneumoperitoneumGastrointestinal disorders1/30/60/340/460/440/50/4
Pneumonia aspirationInfections and infestations1/30/60/340/460/440/50/4
Respiratory distressRespiratory, thoracic and mediastinal disorders1/30/60/340/460/441/50/4
Disease progressionGeneral disorders0/30/610/340/461/440/50/4
Pancreatitis acuteGastrointestinal disorders0/30/60/340/460/441/50/4
General physical health deteriorationGeneral disorders0/30/62/341/460/441/50/4
Ischaemic strokeNervous system disorders0/31/60/340/460/440/50/4
Neurological symptomNervous system disorders0/31/60/340/460/440/50/4
DyspnoeaRespiratory, thoracic and mediastinal disorders0/31/62/341/460/440/50/4
PneumothoraxRespiratory, thoracic and mediastinal disorders0/31/60/340/460/440/50/4
Most frequent other events
Showing 10 of 403
Most frequent other events
EventPhase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab
DiarrhoeaGastrointestinal disorders1/33/65/3417/4613/444/52/4
AnaemiaBlood and lymphatic system disorders2/30/615/3417/4613/442/50/4
AstheniaGeneral disorders2/33/69/3416/4614/441/52/4
Injection site erythemaGeneral disorders1/34/68/3412/460/441/50/4
PyrexiaGeneral disorders2/33/614/3418/468/442/50/4
Abdominal painGastrointestinal disorders0/30/64/349/468/441/52/4
NauseaGastrointestinal disorders1/30/66/348/466/441/52/4
FatigueGeneral disorders0/33/68/349/4610/442/52/4
ArthralgiaMusculoskeletal and connective tissue disorders0/32/65/3411/469/442/52/4
CoughRespiratory, thoracic and mediastinal disorders0/33/62/349/466/441/51/4

Baseline characteristics

In phase I and phase II part 1: all participants included and who received any amount of study treatment will be included in the SAF. Any participant who is assigned a participants number but does not receive any study treatment will not be included in the SAF. In phase II part 2: all randomized participants who were administered at least one dose of IMP(s) according to the treatment allocated at randomization will be included in the SAF.

Age, Categorical
Age, Categorical(Participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
<=18 years00000000
Between 18 and 65 years3325373042104
>=65 years0399141238
Age, Continuous
Age, Continuous(years)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
Median52.0 (45.0 to 56.0)65.5 (51.0 to 68.0)56.0 (48.0 to 67.0)57.0 (50.0 to 61.0)56.5 (46.5 to 66.5)43.0 (41.0 to 54.0)67.5 (57.0 to 75.5)56.0 (48.0 to 66.0)
Sex: Female, Male
Sex: Female, Male(Participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
Female2225434454125
Male149300017
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
Count of participants———————0
Region of Enrollment
Region of Enrollment(participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
United States00010001
France3634393744127
Spain000671014
Primary tumor location
Primary tumor location(Participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
Cervical01825243061
Anal201714132452
Oropharyngeal145000010
Vaginal01323009
Vulvar00144009
Penile00010001
ECOG Performance Status
ECOG Performance Status(Participants)Phase I - TG4001 5x10e6 Pfu + AvelumabPhase I - TG4001 5x10e7 Pfu + AvelumabPhase II Part 1 - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort A - Participants Without Liver Metastases - AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + AvelumabPhase II Part 2 - Cohort B - Participants With Liver Metastases - AvelumabTotal
ECOG Status 0041018113147
ECOG Status 1322428332395
08

Study locations

20 sites
09

References and documents

Publications

  • Borcoman E, Lalanne A, Delord JP, Cassier PA, Rolland F, Salas S, Limacher JM, Capitain O, Lantz O, Ekwegbara C, Jeannot E, Cyrta J, Tran-Perennou C, Castel-Ajgal Z, Marret G, Piaggio E, Brandely M, Tavernaro A, Makhloufi H, Bendjama K, Le Tourneau C. Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers. Eur J Cancer. 2023 Sep;191:112981. doi: 10.1016/j.ejca.2023.112981. Epub 2023 Jul 11. PubMed 37506588 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2024, 84 months.

Results were first posted in Dec 2025, 1 year 2 months after primary completion.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 84 months is above that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2017
First posted
Aug 24, 2017
StartActual
Sep 1, 2017
Primary completionActual
Sep 18, 2024
CompletionEst.
Dec 2026
Results first posted
Dec 2, 2025
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03260023
Lead sponsor
Transgene
Responsible party
Sponsor
First posted
Aug 24, 2017
Start date
Sep 1, 2017
Primary completion
Sep 18, 2024
Completion
Dec 2026 (estimated)
Results posted
Dec 2, 2025
Last update
Feb 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avelumab

Start the discussion